Journal: eLife

Article Title: TRIM37 prevents formation of centriolar protein assemblies by regulating Centrobin

doi: 10.7554/eLife.62640

Figure Lengend Snippet:

Article Snippet: Antibody , Anti-TRIM37 (Rabbit polyclonal) , Bethyl Laboratories , A301-174A , WB (1/1000).

Techniques: Plasmid Preparation, Expressing, Mutagenesis, Recombinant, Sequencing, Negative Control

Journal:

Article Title: An Elaborate Pathway Required for Ras-Mediated Epigenetic Silencing

doi: 10.1038/nature06251

Figure Lengend Snippet: Genes required for Ras-mediated epigenetic silencing of Fas

Article Snippet: Chromatin immunoprecipitation (ChIP) and methylated DNA immunoprecipitation (MeDIP) The following antibodies were used: anti-5-methyl cytosine (ab1884; Abcam), anti-EZH2 (4905; Cell Signaling Technology), anti-CTCF (07-729; Upstate), anti-BMI1 (ab14389; Abcam), anti-DNMT1 (IMG-261A; Imgenex), anti-SIRT6 (ASB- {"type":"entrez-protein","attrs":{"text":"ARP32409","term_id":"1190163317","term_text":"ARP32409"}} ARP32409 ; Aviva Systems Biology), anti-TRIM37 (a gift from A.E.

Techniques: Transduction, Binding Assay, Modification, Histone Deacetylase Assay

Journal: Molecular Medicine Reports

Article Title: TRIM37 promotes epithelial-mesenchymal transition in colorectal cancer

doi: 10.3892/mmr.2017.6125

Figure Lengend Snippet: mRNA and protein expression levels of TRIM37 are increased in CRC cells relative to normal cells. (A) The mRNA expression level of TRIM37 in 30 paired CRC samples and adjacent normal tissues was detected by reverse transcription-quantitative polymerase chain reaction. The TRIM37 expression was normalized to β-actin. *P<0.001. (B) Representative immunohistochemical images of TRIM37 in matched CRC tissues (lower panel) and adjacent non-cancerous tissues (upper panel). Magnification, ×200. (C) Western blot analysis was used to examine the protein expression level of TRIM37 in CRC samples and paired adjacent normal tissues. CRC, colorectal cancer; TRIM37, tripartite motif containing 37; T, CRC tissues; N, non-cancerous adjacent tissues.

Article Snippet: Primary antibodies for TRIM37 (1:500; cat. no. sc-49548, Santa Cruz Biotechnology, Inc.), GAPDH (1:1,000; cat. no. sc-293335, Santa Cruz Biotechnology, Inc.), E-cadherin (1:500; cat. no. ab76055, Abcam, Cambridge, UK), N-cadherin (1:500; cat. no. ab12221, Abcam) and vimentin (1;500; cat. no. ab72547, Abcam) were incubated overnight at 4°C.

Techniques: Expressing, Real-time Polymerase Chain Reaction, Immunohistochemical staining, Western Blot

Journal: Molecular Medicine Reports

Article Title: TRIM37 promotes epithelial-mesenchymal transition in colorectal cancer

doi: 10.3892/mmr.2017.6125

Figure Lengend Snippet: TRIM37 promotes the proliferation, migration and invasion abilities in CRC cells. (A) TRIM37-KD in SW620 cells inhibited cell proliferation, whereas TRIM37-OV in SW480 cells increased proliferation. *P<0.05. (B) Crystal violet assay was used to analyze the effects of TRIM37 on the growth of CRC cells. (C) Representative images of the wound healing assay of TRIM37-KD and TRIM37-OV cells with control. Magnification, ×200. (D) Representative images of the Transwell assays of TRIM37-KD and TRIM37-OV cells with control. Magnification, ×200. Data are representative of three independent experiments. CRC, colorectal cancer; TRIM37, tripartite motif containing 37; TRIM 37-KD, TRIM37 knockdown; TRIM37-OV, TRIM37 overexpression.

Article Snippet: Primary antibodies for TRIM37 (1:500; cat. no. sc-49548, Santa Cruz Biotechnology, Inc.), GAPDH (1:1,000; cat. no. sc-293335, Santa Cruz Biotechnology, Inc.), E-cadherin (1:500; cat. no. ab76055, Abcam, Cambridge, UK), N-cadherin (1:500; cat. no. ab12221, Abcam) and vimentin (1;500; cat. no. ab72547, Abcam) were incubated overnight at 4°C.

Techniques: Migration, Crystal Violet Assay, Wound Healing Assay, Over Expression

Journal: Molecular Medicine Reports

Article Title: TRIM37 promotes epithelial-mesenchymal transition in colorectal cancer

doi: 10.3892/mmr.2017.6125

Figure Lengend Snippet: TRIM37 promotes the invasion of colorectal cancer cells via EMT. (A) Reverse transcription-quantitative polymerase chain reaction was performed to determine the levels of several components that were involved in EMT. In the TRIM37-KD SW620 cells, N-CAD and VIM were downregulated, whereas E-CAD was upregulated. *P<0.05. (B) In the TRIM37-OV SW480 cells, N-CAD and VIM were upregulated, whereas E-CAD was downregulated. *P<0.05. (C) Western blot analysis demonstrated that, in TRIM37-KD SW620 cells, the epithelial marker E-CAD was upregulated, whereas N-CAD and VIM, the mesenchymal markers, were downregulated. (D) In TRIM37-OV SW480 cells, E-CAD was downregulated, whereas N-CAD and VIM were upregulated. TRIM37, tripartite motif containing 37; TRIM 37-KD, TRIM37 knockdown; TRIM37-OV, TRIM37 overexpression; E-CAD, E-cadherin; N-CAD, N-cadherin; VIM, vimentin.

Article Snippet: Primary antibodies for TRIM37 (1:500; cat. no. sc-49548, Santa Cruz Biotechnology, Inc.), GAPDH (1:1,000; cat. no. sc-293335, Santa Cruz Biotechnology, Inc.), E-cadherin (1:500; cat. no. ab76055, Abcam, Cambridge, UK), N-cadherin (1:500; cat. no. ab12221, Abcam) and vimentin (1;500; cat. no. ab72547, Abcam) were incubated overnight at 4°C.

Techniques: Real-time Polymerase Chain Reaction, Western Blot, Marker, Over Expression

Journal: OncoTargets and therapy

Article Title: TRIM37 targets AKT in the growth of lung cancer cells

doi: 10.2147/OTT.S183303

Figure Lengend Snippet: Expression of TRIM37 in lung cancer tissues and cell lines. Notes: ( A ) The mRNA expression of TRIM37 in lung cancer and matched para-cancerous tissues (n=30 for each group). *** P <0.001 vs normal. ( B ) The protein level of TRIM37 in lung cancer and matched para-cancerous tissues (n=8 for each group). *** P <0.001 vs normal. ( C ) The protein level of TRIM37 analyzed by immunohistochemistry in lung cancer and matched para-cancerous tissues. ( D and E ) The mRNA and protein expression level of TRIM37 in different lung cancer cell lines, respectively. *** P <0.001 vs 16HBE cells.

Article Snippet: TRIM37 , CST, Danvers, MA, USA , 1:1,000.

Techniques: Expressing, Immunohistochemistry

Journal: OncoTargets and therapy

Article Title: TRIM37 targets AKT in the growth of lung cancer cells

doi: 10.2147/OTT.S183303

Figure Lengend Snippet: Knockdown and overexpression of TRIM37 in lung cancer cell lines. Notes: ( A and B ) The mRNA and protein level of TRIM37 after transfection of siRNAs into H358 and H292 cells, respectively. *** P <0.001 vs siNC. ( C and D ) The mRNA and protein level of TRIM37 after transfection of oeTRIM37 into H1299 cells. *** P <0.001 vs oeNC. Abbreviation: BLANK, blank control.

Article Snippet: TRIM37 , CST, Danvers, MA, USA , 1:1,000.

Techniques: Over Expression, Transfection

Journal: OncoTargets and therapy

Article Title: TRIM37 targets AKT in the growth of lung cancer cells

doi: 10.2147/OTT.S183303

Figure Lengend Snippet: Knockdown of TRIM37 inhibited cell proliferation and apoptosis. Notes: ( A ) Cell proliferation was detected at 0, 24, 48, and 72 hours after transfection with siNC, siTRIM371-1, and siTRIM371-2 in H358 and H292 cells. ** P <0.01 vs siNC, and *** P <0.001 vs siNC. ( B ) Cell apoptosis profile of cells as indicated above. *** P <0.001 vs siNC. ( C and D ) H292 and H358 cells transfected with indicated TRIM37 siRNAs, and cell migration and invasion were analyzed as described in the “Materials and methods” section, respectively. Magnification, ×200. *** P <0.001 vs siNC group. ( E ) The mRNA expression level of BCL2 and BAX in cells as indicated above. *** P <0.001 vs siNC. ( F ) The protein level of BCL2, BAX, AKT, and p-AKT in cells as indicated above. *** P <0.001 vs siNC. Abbreviation: BLANK, blank control.

Article Snippet: TRIM37 , CST, Danvers, MA, USA , 1:1,000.

Techniques: Transfection, Migration, Expressing

Journal: OncoTargets and therapy

Article Title: TRIM37 targets AKT in the growth of lung cancer cells

doi: 10.2147/OTT.S183303

Figure Lengend Snippet: The function of TRIM37 was inhibited by a specific AKT inhibitor LY294002. Notes: ( A ) Cell proliferation was detected at 0, 24, 48, and 72 hours after transfection with oeNC, oeNC + LY294002, oeTRIM37, and oeTRIM37 + LY294002 in H1299 cells. * P <0.05 vs oeNC, ** P <0.01 vs oeNC, and *** P <0.001 vs oeNC. ( B ) Cell apoptosis profile of cells as indicated above. ** P <0.01 vs oeNC and *** P <0.001 vs oeNC. ( C ) The cell migration and invasion data of H1299 cells transfected with oeNC and oeTRIM37 as well as treated with LY294002. ** P <0.01 vs oeNC and *** P <0.001 vs oeNC. ( D ) The protein level of BCL2, BAX, AKT, and p-AKT in cells as indicated above. ** P <0.01 vs oeNC and *** P <0.001 vs oeNC.

Article Snippet: TRIM37 , CST, Danvers, MA, USA , 1:1,000.

Techniques: Transfection, Migration

Journal: OncoTargets and therapy

Article Title: TRIM37 targets AKT in the growth of lung cancer cells

doi: 10.2147/OTT.S183303

Figure Lengend Snippet: Knockdown of TRIM37 in lung cancer cells inhibited tumor growth in vivo. Notes: H358 cells transfected with siRNA control (siNC) or siTRIM37 were subcutaneously injected into athymic nude mice. ( A and B ) The tumor volume and weight in nude mice injected with H358 cells transfected with siNC and siTRIM37. * P <0.05 vs siNC, ** P <0.01 vs siNC, and *** P <0.001 vs siNC. ( C ) The survival rate of nude mice injected with H358 cells transfected with siNC and siTRIM37.

Article Snippet: TRIM37 , CST, Danvers, MA, USA , 1:1,000.

Techniques: In Vivo, Transfection, Injection

Journal: OncoTargets and therapy

Article Title: TRIM37 targets AKT in the growth of lung cancer cells

doi: 10.2147/OTT.S183303

Figure Lengend Snippet: Homo sapiens TRIM37 (NM_001005207.4) RNAi targeting locus information

Article Snippet: TRIM37 , CST, Danvers, MA, USA , 1:1,000.

Techniques: Sequencing

Journal: OncoTargets and therapy

Article Title: TRIM37 targets AKT in the growth of lung cancer cells

doi: 10.2147/OTT.S183303

Figure Lengend Snippet: The primary antibodies information

Article Snippet: TRIM37 , CST, Danvers, MA, USA , 1:1,000.

Techniques: